Obefazimod

Summary

Obefazimod (CHEMBL4297344) is a phase-3 clinical-stage small molecule; indicated across 5 conditions including ulcerative colitis and crohn disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 5 conditions
• Clinical trials: 19
• Chemistry: 338.71 Da · C16H10ClF3N2O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297344
Name	Obefazimod
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	49846599
Molecular formula	C16H10ClF3N2O
Molecular weight	338.71
InChIKey	OZOGDCZJYVSUBR-UHFFFAOYSA-N

SMILES: C1=CC2=C(C(=C1)Cl)N=C(C=C2)NC3=CC=C(C=C3)OC(F)(F)F

IUPAC name: 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine

Also known as: Abx 464, Abx-464, ABX-464, Abx464, ABX464, Obefazimod, SPL-464, OBEFAZIMOD, C0088674

Patent coverage: 296 distinct patent families (964 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
ulcerative colitis	3	MONDO:0005101	EFO:0000729
Crohn disease	2	MONDO:0005011	EFO:0000384
rheumatoid arthritis	2	MONDO:0008383	EFO:0000685
HIV infectious disease	2	MONDO:0005109	EFO:0000764
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096

Clinical trials

Total trials: 19.

Phase distribution

Phase	Trials
PHASE2	10
PHASE3	3
PHASE1	3
PHASE2/PHASE3	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05535946	PHASE3	ACTIVE_NOT_RECRUITING	ABTECT - Maintenance
NCT03905109	PHASE2/PHASE3	WITHDRAWN	Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn’s Disease Patients
NCT04393038	PHASE2/PHASE3	TERMINATED	ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
NCT05507203	PHASE3	COMPLETED	ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
NCT05507216	PHASE3	COMPLETED	ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
NCT05177835	PHASE2	ACTIVE_NOT_RECRUITING	Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
NCT06456593	PHASE2	RECRUITING	Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn’s Disease
NCT02452242	PHASE2	COMPLETED	Safety, PK and PD Study of ABX464 in Untreated HIV Patients
NCT02735863	PHASE2	COMPLETED	ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment
NCT02990325	PHASE1/PHASE2	COMPLETED	A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults
NCT03093259	PHASE2	COMPLETED	ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
NCT03368118	PHASE2	COMPLETED	Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis
NCT03760003	PHASE2	COMPLETED	Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
NCT03813199	PHASE2	COMPLETED	Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis
NCT04023396	PHASE2	COMPLETED	Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis
NCT04049448	PHASE2	COMPLETED	Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis
NCT02792686	PHASE1	COMPLETED	ABX464 First in Man Study
NCT05032560	PHASE1	COMPLETED	Safety and Pharmacokinetics Study in Healthy Japanese Volunteers
NCT05121714	PHASE1	COMPLETED	Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).